These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18640857)

  • 1. DBC2 gene is silenced by promoter methylation in bladder cancer.
    Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
    Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.
    Knowles MA; Aveyard JS; Taylor CF; Harnden P; Bass S
    Cancer Lett; 2005 Jul; 225(1):121-30. PubMed ID: 15922864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
    Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
    Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of the DBC2 gene in gastric cancer.
    Cho YG; Choi BJ; Kim CJ; Song JH; Zhang C; Nam SW; Lee JY; Park WS
    Acta Oncol; 2008; 47(3):366-71. PubMed ID: 17906984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
    Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
    Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGSF4 promoter methylation and expression silencing in human cervical cancer.
    Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
    Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation.
    Han L; Hou L; Song J; Lin D; Wu L; Ge Y; Ma Z
    Biotechnol Lett; 2013 Aug; 35(8):1175-81. PubMed ID: 23546941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
    Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT
    Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
    Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
    J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
    Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
    Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.